A citation-based method for searching scientific literature

Wenya Linda Bi, Noah F Greenwald, Malak Abedalthagafi, Jeremiah Wala, Will J Gibson, Pankaj K Agarwalla, Peleg Horowitz, Steven E Schumacher, Ekaterina Esaulova, Yu Mei, Aaron Chevalier, Matthew Ducar, Aaron R Thorner, Paul van Hummelen, Anat Stemmer-Rachamimov, Maksym Artyomov, Ossama Al-Mefty, Gavin P Dunn, Sandro Santagata, Ian F Dunn, Rameen Beroukhim. NPJ Genom Med 2017
Times Cited: 85







List of co-cited articles
575 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Genomic analysis of non-NF2 meningiomas reveals mutations in TRAF7, KLF4, AKT1, and SMO.
Victoria E Clark, E Zeynep Erson-Omay, Akdes Serin, Jun Yin, Justin Cotney, Koray Ozduman, Timuçin Avşar, Jie Li, Phillip B Murray, Octavian Henegariu,[...]. Science 2013
486
61

Genomic sequencing of meningiomas identifies oncogenic SMO and AKT1 mutations.
Priscilla K Brastianos, Peleg M Horowitz, Sandro Santagata, Robert T Jones, Aaron McKenna, Gad Getz, Keith L Ligon, Emanuele Palescandolo, Paul Van Hummelen, Matthew D Ducar,[...]. Nat Genet 2013
377
60

DNA methylation-based classification and grading system for meningioma: a multicentre, retrospective analysis.
Felix Sahm, Daniel Schrimpf, Damian Stichel, David T W Jones, Thomas Hielscher, Sebastian Schefzyk, Konstantin Okonechnikov, Christian Koelsche, David E Reuss, David Capper,[...]. Lancet Oncol 2017
330
57

Recurrent somatic mutations in POLR2A define a distinct subset of meningiomas.
Victoria E Clark, Akdes Serin Harmancı, Hanwen Bai, Mark W Youngblood, Tong Ihn Lee, Jacob F Baranoski, A Gulhan Ercan-Sencicek, Brian J Abraham, Abraham S Weintraub, Denes Hnisz,[...]. Nat Genet 2016
171
45

Oncogenic PI3K mutations are as common as AKT1 and SMO mutations in meningioma.
Malak Abedalthagafi, Wenya Linda Bi, Ayal A Aizer, Parker H Merrill, Ryan Brewster, Pankaj K Agarwalla, Marc L Listewnik, Dora Dias-Santagata, Aaron R Thorner, Paul Van Hummelen,[...]. Neuro Oncol 2016
148
41

The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary.
David N Louis, Arie Perry, Guido Reifenberger, Andreas von Deimling, Dominique Figarella-Branger, Webster K Cavenee, Hiroko Ohgaki, Otmar D Wiestler, Paul Kleihues, David W Ellison. Acta Neuropathol 2016
40

Integrated genomic analyses of de novo pathways underlying atypical meningiomas.
Akdes Serin Harmancı, Mark W Youngblood, Victoria E Clark, Süleyman Coşkun, Octavian Henegariu, Daniel Duran, E Zeynep Erson-Omay, Leon D Kaulen, Tong Ihn Lee, Brian J Abraham,[...]. Nat Commun 2017
91
37

TERT Promoter Mutations and Risk of Recurrence in Meningioma.
Felix Sahm, Daniel Schrimpf, Adriana Olar, Christian Koelsche, David Reuss, Juliane Bissel, Annekathrin Kratz, David Capper, Sebastian Schefzyk, Thomas Hielscher,[...]. J Natl Cancer Inst 2015
188
37

BAP1 mutations in high-grade meningioma: implications for patient care.
Ganesh M Shankar, Sandro Santagata. Neuro Oncol 2017
80
33

High incidence of activating TERT promoter mutations in meningiomas undergoing malignant progression.
Stéphane Goutagny, Jean C Nault, Maxime Mallet, Dominique Henin, Jessica Z Rossi, Michel Kalamarides. Brain Pathol 2014
158
30

Secretory meningiomas are defined by combined KLF4 K409Q and TRAF7 mutations.
David E Reuss, Rosario M Piro, David T W Jones, Matthias Simon, Ralf Ketter, Marcel Kool, Albert Becker, Felix Sahm, Stefan Pusch, Jochen Meyer,[...]. Acta Neuropathol 2013
146
28

DNA methylation profiling to predict recurrence risk in meningioma: development and validation of a nomogram to optimize clinical management.
Farshad Nassiri, Yasin Mamatjan, Suganth Suppiah, Jetan H Badhiwala, Sheila Mansouri, Shirin Karimi, Olli Saarela, Laila Poisson, Irina Gepfner-Tuma, Jens Schittenhelm,[...]. Neuro Oncol 2019
83
25

Germline and somatic BAP1 mutations in high-grade rhabdoid meningiomas.
Ganesh M Shankar, Malak Abedalthagafi, Rachael A Vaubel, Parker H Merrill, Naema Nayyar, Corey M Gill, Ryan Brewster, Wenya Linda Bi, Pankaj K Agarwalla, Aaron R Thorner,[...]. Neuro Oncol 2017
67
29

Global epigenetic profiling identifies methylation subgroups associated with recurrence-free survival in meningioma.
Adriana Olar, Khalida M Wani, Charmaine D Wilson, Gelareh Zadeh, Franco DeMonte, David T W Jones, Stefan M Pfister, Erik P Sulman, Kenneth D Aldape. Acta Neuropathol 2017
71
28

Evidence for the complete inactivation of the NF2 gene in the majority of sporadic meningiomas.
M H Ruttledge, J Sarrazin, S Rangaratnam, C M Phelan, E Twist, P Merel, O Delattre, G Thomas, M Nordenskjöld, V P Collins. Nat Genet 1994
443
22

Meningiomas: knowledge base, treatment outcomes, and uncertainties. A RANO review.
Leland Rogers, Igor Barani, Marc Chamberlain, Thomas J Kaley, Michael McDermott, Jeffrey Raizer, David Schiff, Damien C Weber, Patrick Y Wen, Michael A Vogelbaum. J Neurosurg 2015
304
22

EANO guidelines for the diagnosis and treatment of meningiomas.
Roland Goldbrunner, Giuseppe Minniti, Matthias Preusser, Michael D Jenkinson, Kita Sallabanda, Emmanuel Houdart, Andreas von Deimling, Pantelis Stavrinou, Florence Lefranc, Morten Lund-Johansen,[...]. Lancet Oncol 2016
377
21

Increased expression of the immune modulatory molecule PD-L1 (CD274) in anaplastic meningioma.
Ziming Du, Malak Abedalthagafi, Ayal A Aizer, Allison R McHenry, Heather H Sun, Mark-Anthony Bray, Omar Viramontes, Revaz Machaidze, Priscilla K Brastianos, David A Reardon,[...]. Oncotarget 2015
87
21

Intratumoral heterogeneity and TERT promoter mutations in progressive/higher-grade meningiomas.
Tareq A Juratli, Christian Thiede, Mara V A Koerner, Shilpa S Tummala, Dirk Daubner, Ganesh M Shankar, Erik A Williams, Maria Martinez-Lage, Silke Soucek, Katja Robel,[...]. Oncotarget 2017
62
27

SMO mutation status defines a distinct and frequent molecular subgroup in olfactory groove meningiomas.
Julien Boetto, Franck Bielle, Marc Sanson, Matthieu Peyre, Michel Kalamarides. Neuro Oncol 2017
51
31

Expression and prognostic impact of immune modulatory molecule PD-L1 in meningioma.
Seunggu J Han, Gerald Reis, Gary Kohanbash, Shruti Shrivastav, Stephen T Magill, Annette M Molinaro, Michael W McDermott, Philip V Theodosopoulos, Manish K Aghi, Mitchel S Berger,[...]. J Neurooncol 2016
55
29

Loss-of-function mutations in SMARCE1 cause an inherited disorder of multiple spinal meningiomas.
Miriam J Smith, James O'Sullivan, Sanjeev S Bhaskar, Kristen D Hadfield, Gemma Poke, John Caird, Saba Sharif, Diana Eccles, David Fitzpatrick, Daniel Rawluk,[...]. Nat Genet 2013
154
17

Frequent AKT1E17K mutations in skull base meningiomas are associated with mTOR and ERK1/2 activation and reduced time to tumor recurrence.
Ümmügülsüm Yesilöz, Elmar Kirches, Christian Hartmann, Johannes Scholz, Siegfried Kropf, Felix Sahm, Makoto Nakamura, Christian Mawrin. Neuro Oncol 2017
47
31


Genomic profiling reveals alternative genetic pathways of meningioma malignant progression dependent on the underlying NF2 status.
Stéphane Goutagny, Hong Wei Yang, Jessica Zucman-Rossi, Jennifer Chan, Jonathan M Dreyfuss, Peter J Park, Peter M Black, Marco Giovannini, Rona S Carroll, Michel Kalamarides. Clin Cancer Res 2010
69
20

Epidemiology and etiology of meningioma.
Joseph Wiemels, Margaret Wrensch, Elizabeth B Claus. J Neurooncol 2010
585
15

Alterations of the tumor suppressor genes CDKN2A (p16(INK4a)), p14(ARF), CDKN2B (p15(INK4b)), and CDKN2C (p18(INK4c)) in atypical and anaplastic meningiomas.
J Boström, B Meyer-Puttlitz, M Wolter, B Blaschke, R G Weber, P Lichter, K Ichimura, V P Collins, G Reifenberger. Am J Pathol 2001
179
15

Genetic landscape of meningioma.
Sayaka Yuzawa, Hiroshi Nishihara, Shinya Tanaka. Brain Tumor Pathol 2016
66
19

NF2/merlin is a novel negative regulator of mTOR complex 1, and activation of mTORC1 is associated with meningioma and schwannoma growth.
Marianne F James, Sangyeul Han, Carolyn Polizzano, Scott R Plotkin, Brendan D Manning, Anat O Stemmer-Rachamimov, James F Gusella, Vijaya Ramesh. Mol Cell Biol 2009
185
14

Durable Control of Metastatic AKT1-Mutant WHO Grade 1 Meningothelial Meningioma by the AKT Inhibitor, AZD5363.
Michael Weller, Patrick Roth, Felix Sahm, Isabel Burghardt, Bernhard Schuknecht, Elisabeth J Rushing, Luca Regli, Justin P Lindemann, Andreas von Deimling. J Natl Cancer Inst 2017
28
42

A phase II trial of bevacizumab and everolimus as treatment for patients with refractory, progressive intracranial meningioma.
Kent C Shih, Sajeel Chowdhary, Paul Rosenblatt, Alva B Weir, Gregg C Shepard, Jeffrey T Williams, Mythili Shastry, Howard A Burris, John D Hainsworth. J Neurooncol 2016
50
24

Historical benchmarks for medical therapy trials in surgery- and radiation-refractory meningioma: a RANO review.
Thomas Kaley, Igor Barani, Marc Chamberlain, Michael McDermott, Katherine Panageas, Jeffrey Raizer, Leland Rogers, David Schiff, Michael Vogelbaum, Damien Weber,[...]. Neuro Oncol 2014
125
14

Targeted sequencing of SMO and AKT1 in anterior skull base meningiomas.
Matthew R Strickland, Corey M Gill, Naema Nayyar, Megan R D'Andrea, Christian Thiede, Tareq A Juratli, Gabriele Schackert, Darrell R Borger, Sandro Santagata, Matthew P Frosch,[...]. J Neurosurg 2017
32
37

Genomic landscape of intracranial meningiomas.
Wenya Linda Bi, Malak Abedalthagafi, Peleg Horowitz, Pankaj K Agarwalla, Yu Mei, Ayal A Aizer, Ryan Brewster, Gavin P Dunn, Ossama Al-Mefty, Brian M Alexander,[...]. J Neurosurg 2016
60
20

Correlations between genomic subgroup and clinical features in a cohort of more than 3000 meningiomas.
Mark W Youngblood, Daniel Duran, Julio D Montejo, Chang Li, Sacit Bulent Omay, Koray Özduman, Amar H Sheth, Amy Y Zhao, Evgeniya Tyrtova, Danielle F Miyagishima,[...]. J Neurosurg 2019
40
30

Everolimus and Octreotide for Patients with Recurrent Meningioma: Results from the Phase II CEVOREM Trial.
Thomas Graillon, Marc Sanson, Chantal Campello, Ahmed Idbaih, Matthieu Peyre, Hadrien Peyrière, Noémie Basset, Didier Autran, Catherine Roche, Michel Kalamarides,[...]. Clin Cancer Res 2020
39
30

Identification of a progenitor cell of origin capable of generating diverse meningioma histological subtypes.
M Kalamarides, A O Stemmer-Rachamimov, M Niwa-Kawakita, F Chareyre, E Taranchon, Z-Y Han, C Martinelli, E A Lusis, B Hegedus, D H Gutmann,[...]. Oncogene 2011
93
12

Phase II trial of sunitinib for recurrent and progressive atypical and anaplastic meningioma.
Thomas J Kaley, Patrick Wen, David Schiff, Keith Ligon, Sam Haidar, Sasan Karimi, Andrew B Lassman, Craig P Nolan, Lisa M DeAngelis, Igor Gavrilovic,[...]. Neuro Oncol 2015
143
12

Mismatch repair deficiency in high-grade meningioma: a rare but recurrent event associated with dramatic immune activation and clinical response to PD-1 blockade.
Ian F Dunn, Ziming Du, Mehdi Touat, Michael B Sisti, Patrick Y Wen, Renato Umeton, Adrian M Dubuc, Matthew Ducar, Peter D Canoll, Eric Severson,[...]. JCO Precis Oncol 2018
33
33

Molecular profiling predicts meningioma recurrence and reveals loss of DREAM complex repression in aggressive tumors.
Akash J Patel, Ying-Wooi Wan, Rami Al-Ouran, Jean-Pierre Revelli, Maria F Cardenas, Mazen Oneissi, Liu Xi, Ali Jalali, John F Magnotti, Donna M Muzny,[...]. Proc Natl Acad Sci U S A 2019
43
25

CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2012-2016.
Quinn T Ostrom, Gino Cioffi, Haley Gittleman, Nirav Patil, Kristin Waite, Carol Kruchko, Jill S Barnholtz-Sloan. Neuro Oncol 2019
894
12

Pathological classification and molecular genetics of meningiomas.
Christian Mawrin, Arie Perry. J Neurooncol 2010
266
11

A prognostic cytogenetic scoring system to guide the adjuvant management of patients with atypical meningioma.
Ayal A Aizer, Malak Abedalthagafi, Wenya Linda Bi, Margaret C Horvath, Nils D Arvold, Ossama Al-Mefty, Eudocia Q Lee, Lakshmi Nayak, Mikael L Rinne, Andrew D Norden,[...]. Neuro Oncol 2016
48
20

Advances in meningioma genetics: novel therapeutic opportunities.
Matthias Preusser, Priscilla K Brastianos, Christian Mawrin. Nat Rev Neurol 2018
78
12

Loss of histone H3K27me3 identifies a subset of meningiomas with increased risk of recurrence.
Leah M Katz, Thomas Hielscher, Benjamin Liechty, Joshua Silverman, David Zagzag, Rajeev Sen, Peter Wu, John G Golfinos, David Reuss, Marian Christoph Neidert,[...]. Acta Neuropathol 2018
64
15

DMD genomic deletions characterize a subset of progressive/higher-grade meningiomas with poor outcome.
Tareq A Juratli, Devin McCabe, Naema Nayyar, Erik A Williams, Ian M Silverman, Shilpa S Tummala, Alexandria L Fink, Aymen Baig, Maria Martinez-Lage, Martin K Selig,[...]. Acta Neuropathol 2018
40
25

Comprehensive Molecular Profiling Identifies FOXM1 as a Key Transcription Factor for Meningioma Proliferation.
Harish N Vasudevan, Steve E Braunstein, Joanna J Phillips, Melike Pekmezci, Bryan A Tomlin, Ashley Wu, Gerald F Reis, Stephen T Magill, Jie Zhang, Felix Y Feng,[...]. Cell Rep 2018
47
21

An integrated genomic analysis of anaplastic meningioma identifies prognostic molecular signatures.
Grace Collord, Patrick Tarpey, Natalja Kurbatova, Inigo Martincorena, Sebastian Moran, Manuel Castro, Tibor Nagy, Graham Bignell, Francesco Maura, Matthew D Young,[...]. Sci Rep 2018
25
40

TERT promoter mutations are associated with poor prognosis and cell immortalization in meningioma.
Sabine Spiegl-Kreinecker, Daniela Lötsch, Katharina Neumayer, Lucia Kastler, Johannes Gojo, Christine Pirker, Josef Pichler, Serge Weis, Rajiv Kumar, Gerald Webersinke,[...]. Neuro Oncol 2018
53
18

Long-term recurrence rates of atypical meningiomas after gross total resection with or without postoperative adjuvant radiation.
Manish K Aghi, Bob S Carter, Garth R Cosgrove, Robert G Ojemann, Sepideh Amin-Hanjani, Robert L Martuza, William T Curry, Fred G Barker. Neurosurgery 2009
302
11


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.